Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: CUBBY who wrote (1008)	5/28/1998 7:13:00 PM
From: majormember	Respond to of 4140

All: For those who have not seen this, below is a brief summation of S & P "Stock of the Week" report. It amazes me how many people are saying the current price has NASDAQ listing built in. All the Brokers, Analysts, Institutions, etc. who would like to buy now CANNOT do so because of the BB status. As soon as we get listed, those same people have the cover needed to make their recommendations and purchases. Skane ****************************************************************** S&P's MarketScope@Home Stock of the Week ----------------------------------------------------------------------11/19/97 received FDA approval to move into Phase III studies for treating hyperopia... on 12/11/97, SNRS formed a Scientific Advisory Board comprised of leading ophthalmic surgeons from around the world... 1/27/98 completed $9.35 million private financing of which 80% of the money came from ophthalmologists who have seen the clinical data or have experience using the system for treating hyperopia... on 2/24/98, SNRS got conditional FDA approval to treat the second eye on the same day... and on 3/24/98, the co. got FDA approval to begin a study to treat patients who are overcorrected after having a myopic excimer laser procedure resulting in induced hyperopia. On a technical basis, the stock is also quite appealing... SNRS recently broke out to all-time highs on extremely heavy volume... after a brief consolidation on light volume, the stock looks poised to take a run at the intra-day high of $7.5 on its way to $8 to $10. We believe the stock is extremely attractive for speculative accounts on a short term basis and has the potential to be a blockbuster over the next couple of years. With respect to the Bulletin Board listing, the co. expects to be listed on the NASDAQ, NASDAQ small-cap, or AMEX within the next month. /Mark Arbeter